• PD neurotechnology targets €500K on SeedBlink as part of €5M Series A round led by CIC Capital Partners and BigPi Ventures, both participating with a total of €4.5 million
• The Greek medtech startup provides patients with wearable medical devices and advanced AI software for monitoring and treatment.
• The funds will be used for manufacturing purposes, clinical trials and to stimulate commercial development in new markets.
After raising €4.5 million, the Greek medtech startup PD Neurotechnology announced that it is targeting €500,000 in a funding round opened by SeedBlink, the European platform for co-investment in technology startups, as part of a Series A funding round worth €5 million.
Neurotechnology provides patients with Parkinson’s disease and other movement disorders with wearable medical devices and advanced AI software for monitoring and treatment, which can be applied at home or in non-clinical settings.
Founded in 2015, the Greek startup’s team includes 40 specialists in biomedical devices, neurology, healthcare, logistics, artificial intelligence and Parkinson’s disease, with an advisory board including scientists in neurology and Parkinson’s disease.
Invest in clinical trials and expand into new markets
According to PD Neurotechnology, the funds raised in this investment round will be used for manufacturing purposes, clinical trials and to drive commercial development in new markets.
“Our goal has always been to develop innovative, non-invasive solutions to help patients feel safer and to forge a close and effective doctor-patient relationship. Our plans for the future are substantial, we are constantly looking for new sources of growth and we are always looking to diversify and improve the solutions we offer,” said Nikos Moschos, founder and commercial director of Neurotechnology in a statement.
“It’s important that we support MedTech innovators because they not only impact the economy, but they also improve people’s lives. We must strengthen their capacity to provide effective solutions. Significant innovation gives even more meaning to our investment. We are excited about PD Neurotechnology’s products and want to support their growth,” concluded Ionuț Pătrăhău, General Manager and Corporate Development at SeedBlink.
Currently, PD Neurotechnology’s sales and marketing are based in Athens, while R&D and production are located in the city of Ioannina. The Greek company operates in 13 European countries and its launch in the United States is planned for the last quarter of 2022.